^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | mefatinib (MET306) (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase II Trial for Mefatinib (MET-306) in the treatment of EGFR rare mutations (g719x, l861q, s768i) in Patients with advanced non-small cell lung cancer
Excerpt:
...Only carry EGFR non-classical mutations (G719X, L861Q, S768I, mutations can be combined with each other) 6. ...
Trial ID:
Source:
Title:
A Phase III Trial for Mefatinib (MET-306) Versus Gefitinib in the Treatment of 1st Line EGFR Mutation of Patients with Advanced Non-Small Cell Lung Cancer
Excerpt:
...with the presence of EGFR-activating mutation (exon 19 deletion or the L858R mutation in exon 21); 6. ...
Trial ID:
More C2 evidence
Source:
Title:
A phase II trial for Mefatinib (MET-306) 60mg or 80mg in the treatment of 1st Line EGFR Mutation in Patients with advanced non-small cell lung cancer
Excerpt:
...Carry EGFR mutations (Del 19,L858R); 6. ...
Trial ID:
Less C2 evidence
Source:
Title:
Mefatinib as first-line treatment of patients with advanced non–small cell lung cancer harboring rare EGFR mutations.
Published date:
05/26/2022
Excerpt:
Among the 21 efficacy evaluable patients, ORR was 85.71% (95% CI, 63.66-96.95) with a duration of response (DOR) of 22.2 months (95% CI, 8.4-NA). Disease control rate (DCR) was 100% (95% CI, 83.89-100.00). Median progression-free survival (mPFS) was 20.6 months (95% CI, 8.3-NA)....Mefatinib has shown promising anti-tumor activity and a favorable safety profile in patients with advanced NSCLC harboring rare EGFR mutations.
DOI:
10.1200/JCO.2022.40.16_suppl.9102
